Drugs / C. difficile Toxoid Vaccine
C. difficile Toxoid Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00214461 | Nov 2005 → Feb 2006 | Clostridium difficile colitis | Sanofi | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01887912 | Jul 2013 → Jun 2018 | Clostridium infectious disease | Sanofi Pasteur, a Sanofi Company | Terminated | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C. difficile Toxoid Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01887912 ↗ |
| Known as | bivalent C difficile toxoid vaccine | “a bivalent C difficile toxoid vaccine did not prevent C difficile infection” PMID 32946836 ↗ Sep 2020 |
| Known as | C difficile toxoid vaccine candidate | “to receive either a C difficile toxoid vaccine candidate, containing toxoids A and B (C difficile vaccine candidate group), or a placebo vaccine” PMID 32946836 ↗ Sep 2020 |
| Known as | Clostridioides difficile toxoid vaccine candidate | “a Clostridioides difficile toxoid vaccine candidate” PMID 32946836 ↗ Sep 2020 |
| Known as | Clostridium difficile toxoid vaccine | “candidate Clostridium difficile toxoid vaccine (2 μg, 10 μg, or 50 μg)” PMID 22306375 ↗ Feb 2012 |
| Modality | Vaccine | “modified C. difficile vaccine” NCT00214461 ↗ |
| Route | Intramuscular | “Intramuscular on Day 0, Day 28, and Day 56, respectively” NCT00214461 ↗ |